Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Hoth Therapeutics (HOTH) stocks

Learn how to easily invest in Hoth Therapeutics stocks.

Hoth Therapeutics is a biotechnology business based in the US. Hoth Therapeutics stocks (HOTH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.59 – the same closing value as a week prior. Hoth Therapeutics employs 2 staff and has a market cap (total outstanding stock value) of $5.3 million.

How to buy Hoth Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – HOTH. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Hoth Therapeutics stock price (NASDAQ:HOTH)

Use our graph to track the performance of HOTH stocks over time.

Hoth Therapeutics shares at a glance

Information last updated 2023-05-27.
Latest market close$1.59
52-week range$1.52 - $12.75
50-day moving average $1.86
200-day moving average $5.04
Wall St. target price$9.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-7.65

Buy Hoth Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Hoth Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Hoth Therapeutics price performance over time

Historical closes compared with the close of $1.59 from 2023-05-26

1 week (2023-05-22) 1.59
1 month (2023-04-28) -8.09%
3 months (2023-03-01) -43.42%
6 months (2022-11-29) -61.87%
1 year (2022-05-25) N/A
2 years (2021-05-28) 9.66%
3 years (2020-05-29) 2.89
5 years (2018-05-25) N/A
[/expander_content] [/expander]

Hoth Therapeutics financials

Gross profit TTM $0
Return on assets TTM -77.95%
Return on equity TTM -151.59%
Profit margin 0%
Book value $3.93
Market capitalisation $5.3 million

TTM: trailing 12 months

Hoth Therapeutics share dividends

We're not expecting Hoth Therapeutics to pay a dividend over the next 12 months.

Have Hoth Therapeutics's shares ever split?

Hoth Therapeutics's shares were split on a 1:25 basis on 26 October 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hoth Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Hoth Therapeutics shares which in turn could have impacted Hoth Therapeutics's share price.

Hoth Therapeutics share price volatility

Over the last 12 months, Hoth Therapeutics's shares have ranged in value from as little as $1.52 up to $12.745. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hoth Therapeutics's is 0.1153. This would suggest that Hoth Therapeutics's shares are less volatile than average (for this exchange).

Hoth Therapeutics overview

Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc. ; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site